ConductScience.org, home

Paper28291584

Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.

Alley EW and 6 others. Lancet Oncol, 2017. Cited by 389 papers, by iCite.

Cite this record

ConductScience Library. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Papers, record 28291584. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28291584

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
PubMed
Journal
Lancet Oncol
PubMed
Year
2017
PubMed
Publication types
Clinical Trial, Phase I, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
389
iCite
Relative citation ratio, by iCite
12
iCite
Revised in PubMed
2022-04-08
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Alley EWEvan W
2Lopez JJuanita
3Santoro AArmando
4Morosky AAnne
5Saraf SSanatan
6Piperdi BBilal
7van Brummelen EEmilie

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, Monoclonal, HumanizedMajor topic
Antineoplastic AgentsMajor topic
MesotheliomaMajor topic
Pleural NeoplasmsMajor topic
Aged
Arthralgia
B7-H1 Antigen
Fatigue
Female
Humans
Male
Middle Aged
Nausea
Non-Randomized Controlled Trials as Topic
Response Evaluation Criteria in Solid Tumors
Retreatment

Source PubMed

Download CSV of topics

Trials3

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT02054806Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)ResultsYesClinicalTrials.gov
NCT03447678Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.ResultsClinicalTrials.gov
NCT03918252Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural MesotheliomaBackgroundClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in28495276Immune checkpoint inhibitors in malignant pleural mesothelioma.https://conductscience.org/library/papers/28495276

Source PubMed

Download CSV of comments and corrections

Cited by260

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 389 citations.

PMIDTitleJournalYearIn PapersSource
42903807Reprogramming the tumor microenvironment in mesothelioma: from immune suppression to therapeutic opportunity.Front Immunol2026https://conductscience.org/library/papers/42903807PubMed
42806022VISTA drives tumour-intrinsic proliferation in mesothelioma cells.Br J Cancer2026https://conductscience.org/library/papers/42806022PubMed
42201625Gut microbiota and cancer immunotherapy: from dysbiosis to personalized immune checkpoint blockade optimization.Folia Microbiol (Praha)2026https://conductscience.org/library/papers/42201625PubMed
42179971Nicotinamide mononucleotide enhances anti-tumor effect by resetting macrophages toward the inflammatory M1-like phenotype.Mol Ther Oncol2026https://conductscience.org/library/papers/42179971PubMed
41749932Clinical Importance of Molecular Biomarkers in Pleural Mesothelioma.Cancers (Basel)2026https://conductscience.org/library/papers/41749932PubMed
41696561Immunotherapy advances in pleural mesothelioma.Ther Adv Med Oncol2026https://conductscience.org/library/papers/41696561PubMed
41553026Risk Factors of Hematological Toxicity of Mesothelioma Treatment-A Territory-Wide Retrospective Study.Thorac Cancer2026https://conductscience.org/library/papers/41553026PubMed
41510382Real-world outcomes of first-line immunotherapy and subsequent systemic therapies in pleural mesothelioma: a multicenter study in China.Transl Lung Cancer Res2025https://conductscience.org/library/papers/41510382PubMed
41503777Association between immune-related adverse events and prognosis in immune checkpoint inhibitor therapy: A bibliometric and visual analysis.Hum Vaccin Immunother2025https://conductscience.org/library/papers/41503777PubMed
41463268Determinants of Response to Immune Checkpoint Blockade in Pleural Mesothelioma: Molecular, Immunological, and Clinical Perspectives.Cancers (Basel)2025https://conductscience.org/library/papers/41463268PubMed
41463246The Dual Effects of CDK4/6 Inhibitors on Tumor Immunity.Cancers (Basel)2025https://conductscience.org/library/papers/41463246PubMed
41321671Phase 1b Multicenter Study of SG001, a Humanized Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors.Drug Des Devel Ther2025https://conductscience.org/library/papers/41321671PubMed
40904706Pleural Mesothelioma: Pathogenesis, Diagnosis, Treatment, Prognosis, and Survival.MedComm (2020)2025https://conductscience.org/library/papers/40904706PubMed
40874563Harnessing the Gut Microbiome in Cancer Immunotherapy: Mechanisms, Challenges, and Routes to Personalized Medicine-A Systematic Review.Technol Cancer Res Treat2025https://conductscience.org/library/papers/40874563PubMed
40775245Pleural mesothelioma.Nat Rev Dis Primers2025https://conductscience.org/library/papers/40775245PubMed
40506895Molecular Insights into Pleural Mesothelioma: Unveiling Pathogenic Mechanisms and Therapeutic Opportunities.Diagnostics (Basel)2025https://conductscience.org/library/papers/40506895PubMed
40407381KEYNOTE-A17: First-Line Pembrolizumab Plus Cisplatin-Pemetrexed in Japanese Participants With Advanced Pleural Mesothelioma.Cancer Sci2025https://conductscience.org/library/papers/40407381PubMed
40400943A bibliometric analysis of malignant pleural mesothelioma from 2010 to 2023.J Thorac Dis2025https://conductscience.org/library/papers/40400943PubMed
40362535Molecular Mechanisms of Tumor Progression and Novel Therapeutic and Diagnostic Strategies in Mesothelioma.Int J Mol Sci2025https://conductscience.org/library/papers/40362535PubMed
40208070Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma.Clin Cancer Res2025https://conductscience.org/library/papers/40208070PubMed

See all 260 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
PDCD15133PubTator's text mininghttps://conductscience.org/library/genes/5133NCBI Gene

Download CSV of genes

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
PEMBROLIZUMABCHEMBL3137343Results2https://conductscience.org/library/drugs/CHEMBL3137343

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • References
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28291584

GET https://conductscience.org/api/papers/v1/28291584/cited_by?page=2